Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Aerami Therapeutics
Amolyt Pharma
Ascendis Pharma A/S
BridgeBio Pharma Inc
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Pharma
ProLynx LLC
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Hypoparathyroidism - Drug Profiles
ACP-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aerami-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-3601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLTX-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
encaleret - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-6272K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
parathyroid hormone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCO-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem cell Therapy for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teriparatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
Oct 23, 2020: Ascendis Pharma receives Orphan Desigtion for TransCon PTH for treatment of hypoparathyroidism in Europe
Oct 14, 2020: Amolyt Pharma doses first subject in phase 1 clinical trial of parathyroid hormone alog, AZP-3601, for Hypoparathyroidism
Sep 28, 2020: Ascendis Pharma announces prelimiry six-month data from open-label extension of phase 2 PaTH forward trial and files IND amendment to initiate phase 3 PaTHway trial of TransCon PTH in adult hypoparathyroidism
Sep 21, 2020: BridgeBio Pharma’s Calcilytix Therapeutics initiates phase 2 study of encaleret for Autosomal Domint Hypocalcemia Type 1 (ADH1)
Sep 04, 2020: Ascendis Pharma announces presentations for TransCon PTH and hypoparathyroidism at 22nd European Congress of Endocrinology
Jul 07, 2020: ProLynx announces SBIR grant award to develop long-acting parathyroid hormone for hypo-parathyroidism
Apr 19, 2020: Ascendis Pharma announces top-line data from fixed dose portion of phase 2 trial demonstrating potential of TransCon PTH as a replacement therapy for Hypoparathyroidism
Nov 14, 2019: Ascendis Pharma expands TransCon PTH Phase 2 PaTH forward clinical trial to expedite enrollment of subjects previously treated with TPARA in the United States
Oct 18, 2019: Leahy, Sanders, Welch urge FDA to swiftly resolve critical drug recall
Sep 23, 2019: Entera Bio reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with Hypoparathyroidism
Sep 06, 2019: Takeda Issues US Recall of TPARA (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate
May 15, 2019: Takeda to highlight new research into the long-term complications of chronic hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting
Apr 24, 2019: Ascendis Pharma announces presentations related to TransCon PTH at upcoming Medical Conferences
Mar 26, 2019: Takeda presents new data at the Endocrine Society’s 2019 Annual Meeting about the patient burden and long-term impact of chronic hypoparathyroidism
Mar 26, 2019: Ascendis Pharma reports positive results from heiGHt trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Hypoparathyroidism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Hypoparathyroidism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hypoparathyroidism - Pipeline by Aerami Therapeutics, H2 2020
Hypoparathyroidism - Pipeline by Amolyt Pharma, H2 2020
Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H2 2020
Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, H2 2020
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
Hypoparathyroidism - Pipeline by Eli Lilly and Co, H2 2020
Hypoparathyroidism - Pipeline by Entera Bio Ltd, H2 2020
Hypoparathyroidism - Pipeline by Extend Biosciences Inc, H2 2020
Hypoparathyroidism - Pipeline by GC Pharma, H2 2020
Hypoparathyroidism - Pipeline by ProLynx LLC, H2 2020
Hypoparathyroidism - Pipeline by Sigilon Therapeutics Inc, H2 2020
Hypoparathyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Hypoparathyroidism - Dormant Projects, H2 2020